Blood CD9+ B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation - Université Grenoble Alpes Accéder directement au contenu
Article Dans Une Revue American Journal of Transplantation Année : 2019

Blood CD9+ B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation

Carole Brosseau
Richard Danger
  • Fonction : Auteur
Maxim Durand
  • Fonction : Auteur
Eugénie Durand
  • Fonction : Auteur
Aurore Foureau
  • Fonction : Auteur
Philippe Lacoste
  • Fonction : Auteur
Adrien Tissot
  • Fonction : Auteur
Antoine Roux
  • Fonction : Auteur
Martine Reynaud-Gaubert
  • Fonction : Auteur
Romain Kessler
  • Fonction : Auteur
Sacha Mussot
  • Fonction : Auteur
Claire Dromer
  • Fonction : Auteur
Olivier Brugière
  • Fonction : Auteur
Jean François Mornex
  • Fonction : Auteur
Romain Guillemain
  • Fonction : Auteur
Antoine Magnan
  • Fonction : Auteur
Sophie Brouard
  • Fonction : Auteur

Résumé

Bronchiolitis obliterans syndrome is the main limitation for long-term survival after lung transplantation. Some specific B cell populations are associated with long-term graft acceptance. We aimed to monitor the B cell profile during early development of bronchiolitis obliterans syndrome after lung transplantation. The B cell longitudinal profile was analyzed in peripheral blood mononuclear cells from patients with bronchiolitis obliterans syndrome and patients who remained stable over 3 years of follow-up. CD24hi CD38hi transitional B cells were increased in stable patients only, and reached a peak 24 months after transplantation, whereas they remained unchanged in patients who developed a bronchiolitis obliterans syndrome. These CD24hi CD38hi transitional B cells specifically secrete IL-10 and express CD9. Thus, patients with a total CD9+ B cell frequency below 6.6% displayed significantly higher incidence of bronchiolitis obliterans syndrome (AUC = 0.836, PPV = 0.75, NPV = 1). These data are the first to associate IL-10-secreting CD24hi CD38hi transitional B cells expressing CD9 with better allograft outcome in lung transplant recipients. CD9-expressing B cells appear as a contributor to a favorable environment essential for the maintenance of long-term stable graft function and as a new predictive biomarker of bronchiolitis obliterans syndrome-free survival.

Dates et versions

hal-04559367 , version 1 (25-04-2024)

Identifiants

Citer

Carole Brosseau, Richard Danger, Maxim Durand, Eugénie Durand, Aurore Foureau, et al.. Blood CD9+ B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation. American Journal of Transplantation, 2019, 19 (11), pp.3162-3175. ⟨10.1111/ajt.15532⟩. ⟨hal-04559367⟩

Collections

INSERM UGA LBFA
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More